C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

30 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

13 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

10 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

08 Sep 2024 17:05:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

03 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Participate in Upcoming September Investor Conferences

29 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation

14 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

01 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

16 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

08 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

10 Jun 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

08 May 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

29 Apr 2024 15:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

09 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

08 Apr 2024 07:00:01 By Nasdaq GlobeNewswire

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

04 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

22 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

09 Jan 2024 15:01:00 By Nasdaq GlobeNewswire

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

04 Jan 2024 15:01:00 By Nasdaq GlobeNewswire